. Author manuscript; available in PMC: 2013 Jan 29.

Published in final edited form as: Cancer Biomark. 2011;11(1):1–14. doi: 10.3233/CBM-2012-0260

Table 6.

Diagnostic improvement in differentiating resectable PC (EPC) from controls observed when combining PBMC expression analysis with the gold standard CA19-9

	EPC vs HC					EPC vs CP

Test	Composition	AUC	Sensitivity	Specificity	P-value	Composition	AUC	Sensitivity	Specificity	P-value
Gold standard	CA19-9 clinical cutoff > 37U/mL	0.719	74%	27%	0.17	CA19-9 clinical cutoff > 37U/mL	0.704	74%	34%	0.023
	CA19-9 optimal cutoff ≥; 61.7U/mL		70%	80%		CA19-9 optimal cutoff > 74.0 U/mL		65%	80%
Combination test	Panel A^a	0.772	67%	81%		Panel B^b	0.820	67%	83%

EPC, Early Pancreatic Cancer; HC, Healthy Controls; CP, Chronic Pancreatitis; AUC, Area Under the ROC Curve

Panel A represents a combination test consisting of PBMC expression analysis of CA5B, F5, MIC1, and ARG1 along with plasma CA19-9 levels;

Panel B represents a combination test consisting of PBMC expression analysis of CA5B, F5, MIC1, and SSBP2 along with plasma CA19-9 levels.